Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?
Citation
Porter , R J , Andrews , C , Brice , D P , Durum , S K & McLean , M H 2018 , ' Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease? ' , Inflammatory Bowel Diseases , vol. 24 , no. 10 , pp. 2123-2134 . https://doi.org/10.1093/ibd/izy230
Rights
This is a pre-copyedited, author-produced version of an article accepted for publication in Inflammatory Bowel Disease following peer review. The version of recordRoss John Porter, Caroline Andrews, Daniel Paul Brice, Scott Kenneth Durum, Mairi Hall McLean; Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?, Inflammatory Bowel Diseases, Volume 24, Issue 10, 15 September 2018, Pages 2123–2134., is available online at: https://academic.oup.com/ibdjournal/article/24/10/2123/5055343